Revvity (RVTY) Stock Analysis & Winston Score

Revvity makes tools and software that scientists use to study diseases, develop new drugs, and test patients for health conditions. Its products include lab instruments, chemical reagents, and diagnostic tests, sold mainly to hospitals, pharmaceutical companies, and research labs. The company is especially known for newborn screening — its tests help detect rare diseases in babies shortly after birth, and it serves customers in over 190 countries. Revvity earns money by selling instruments upfront and then generating recurring revenue from consumables, software subscriptions, and services that customers need to keep using those instruments. It operates globally, with significant revenue from North America, Europe, and Asia, and generates roughly $2.8 billion in annual revenue. Its large installed base of instruments creates a natural lock-in, since customers tend to keep buying Revvity's consumables once they own its equipment — but slow growth in pharmaceutical research spending remains a key risk to watch.